FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutics and medicine, more specifically to a new 3-(2,2,2-trimethylhydrazinium)propionate derivative, 3-(2,2,2-trimethylhydrazinium)potassium propionate 5-bromnicotinate (CH3)3N+HCH2CH2COOKRCOO- wherein 
.
EFFECT: preparing the compound showing high endothelioprotective activity.
1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 3-(2,2,2-TRIMETHYLHYDRAZINIUM) PROPIONATE DERIVATIVE - 3-(2,2,2-TRIMETHYLHYDRAZINIUM) POTASSIUM PROPIONATE GLYCINATE EXHIBITING ENDOTHELIOPROTECTIVE ACTIVITY | 2011 |
|
RU2467748C1 |
| 3-(2,2,2-TRIMETHYLHYDRAZINIUM) PROPIONATE DERIVATIVE -3-(2,2,2-TRIMETHYLHYDRAZINIUM) POTASSIUM PROPIONATE NICOTINATE DERIVATIVE EXHIBITING ENDOTHELIOPROTECTIVE ACTIVITY | 2011 |
|
RU2465268C1 |
| 3-(2,2,2-TRIMETHYLHYDRAZINIUM) PROPIONATE DERIVATIVE - 3-(2,2,2-TRIMETHYLHYDRAZINIUM) POTASSIUM PROPIONATE 5-NICOTINATE HYDROXIDE EXHIBITING ENDOTHELIOPROTECTIVE ACTIVITY | 2011 |
|
RU2467744C1 |
| 3-(2,2,2-TRIMETHYLHYDRAZINIUM) PROPIONATE-5-BROMNICOTINATE 3-(2,2,2-TRIMETHYLHYDRAZINIUM) POTASSIUM PROPIONATE DERIVATIVE EXHIBITING ANTIISCHEMIC ACTIVITY | 2011 |
|
RU2458690C1 |
| METHOD OF PICAMILONUM-BASED CORRECTION OF ENDOTHELIAL DYSFUNCTION IN L-NAME INDUCED NITRIC OXIDE DEFICIENCY | 2008 |
|
RU2364393C1 |
| METHOD OF TADALAFIL-BASED CORRECTION OF ENDOTHELIAL DYSFUNCTION IN L-NAME INDUCED NITRIC OXIDE DEFICIENCY | 2008 |
|
RU2364395C1 |
| METHOD OF LAMOTRIGINE CORRECTION OF ENDOTHELIAL DYSFUNCTION ASSOCIATED WITH L-NAME INDUCED NITROGEN OXIDE DEFICIENCY | 2008 |
|
RU2367421C1 |
| METHOD OF ACETYLSALICYLIC ACID BASED CORRECTION OF ENDOTHELIAL DYSFUNCTION IN L-NAME INDUCED NITRIC OXIDE DEFICIENCY | 2008 |
|
RU2364392C1 |
| METHOD OF CLOPIDOGREL-BASED CORRECTION OF ENDOTHELIAL DYSFUNCTION IN L-NAME INDUCED NITRIC OXIDE DEFICIENCY | 2008 |
|
RU2364394C1 |
| METHOD FOR CORRECTING ENDOTHELIAL DYSFUNCTION WITH COMBINATION OF INDAPAMIDE AND RESVERATROL AT L-NAME-INDUCED DEFICIENCY OF NITROGEN OXIDE | 2005 |
|
RU2302241C1 |
